Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-07-26
2005-07-26
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S350000, C424S192100, C424S199100, C424S227100, C514S04400A, C536S023400, C536S023720, C435S320100, C435S325000, C435S252300, C435S069300
Reexamination Certificate
active
06921534
ABSTRACT:
The invention relates to HBV antigen-containing compositions that are useful in treating or preventing HBV infection. The content of the compositions can vary, as described herein, but the compositions comprise a stress protein, or a portion (e.g., a fragment) or derivative thereof, and an HBV antigen.
REFERENCES:
patent: 4547368 (1985-10-01), Tabor et al.
patent: 4716038 (1987-12-01), Stanford et al.
patent: 4724144 (1988-02-01), Rook et al.
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5114844 (1992-05-01), Cohen et al.
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5504005 (1996-04-01), Bloom et al.
patent: 5578300 (1996-11-01), Schmidt et al.
patent: 5580563 (1996-12-01), Tam
patent: 5599545 (1997-02-01), Stanford et al.
patent: 5736146 (1998-04-01), Cohen et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5935576 (1999-08-01), Srivastava
patent: 5948646 (1999-09-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6017544 (2000-01-01), Srivastava
patent: 6020167 (2000-02-01), Thoma
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 6130087 (2000-10-01), Srivastava et al.
patent: 6136315 (2000-10-01), Srivastava
patent: 6139841 (2000-10-01), Srivastava
patent: 6143299 (2000-11-01), Srivastava
patent: 6156302 (2000-12-01), Srivastava
patent: 6162436 (2000-12-01), Srivastava
patent: 6168793 (2001-01-01), Srivastava
patent: 6187312 (2001-02-01), Srivastava
patent: 6231864 (2001-05-01), Birkett
patent: 6297048 (2001-10-01), Jolly et al.
patent: 6322790 (2001-11-01), Srivastava
patent: 6335183 (2002-01-01), Young et al.
patent: 6338952 (2002-01-01), Young et al.
patent: 6388952 (2002-05-01), Young et al.
patent: 0 262 710 (1988-04-01), None
patent: 0 322 990 (1989-07-01), None
patent: 2 251 186 (1992-07-01), None
patent: WO 85/05034 (1985-11-01), None
patent: WO 88/00974 (1988-02-01), None
patent: WO 88/05823 (1988-08-01), None
patent: WO 88/06591 (1988-09-01), None
patent: WO 89/12455 (1989-12-01), None
patent: WO 90/15873 (1990-12-01), None
patent: WO 91/02542 (1991-03-01), None
patent: WO 91/15572 (1991-10-01), None
patent: WO 92/08484 (1992-05-01), None
patent: WO 92/08488 (1992-05-01), None
patent: WO 93/17712 (1993-09-01), None
patent: WO 94/03208 (1994-02-01), None
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 95/31994 (1995-11-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/23735 (1998-06-01), None
patent: 98/23735 (1998-06-01), None
patent: WO 98/34641 (1998-08-01), None
patent: WO 98/35705 (1998-08-01), None
patent: WO 99/07860 (1999-02-01), None
patent: WO 00/19828 (2000-04-01), None
patent: WO 00/23093 (2000-04-01), None
patent: WO 01/04344 (2001-01-01), None
patent: WO 02/14370 (2001-02-01), None
patent: WO 01/17554 (2001-03-01), None
patent: WO 01/52791 (2001-07-01), None
patent: WO 01/52877 (2001-07-01), None
patent: WO 01/52890 (2001-07-01), None
patent: WO 01/53457 (2001-07-01), None
patent: WO 02/00242 (2002-01-01), None
Gunther et al (Hepatology 24(4), 751□758, 1996).
Yuan et al (Journal of Virology 73:10122-10128, 1999).
CAA59535 [online] [retrieved 7/22/04]Retrieved from NCBI Entrez Protein http://www.ncbi.nlm.nih.gov/entrez.viewer.fcgi?db=protein&val=762935.
Chen et al. (2004) “Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection” Vaccine 22(3-4):439-46.
Agranovsky et al., “Putative 65 kDa Protein of Beet Yellows Closterovirus Is a Homologue of HSP70 Heat Shock Proteins,” J. Mol. Biol., 217:603-610 (1991).
Anthony et al., “Priming of CD8+CTL Effector Cells In Mice By Immunization With a Stress Protein-Influenza Virus Nucleoprotein Fusion Molecule”, Vaccine, 17:373-383 (1999).
Ardeshir et al., “A 75 Kd Merozoite Surface Protein of Plasmodium Falciparum which is Related to the 70 kd Heat-Shcok Proteins,” EMBO J., 6(2):493-499 (1987).
Arnosti et al., “Characterization of heat shock inBacillus subtilis,” J. Bact., 168(3):1243-1249 (Dec. 1986).
Arrigo and Welch, “Characterization and Purification of the Small 28,000-Dalton Mammalian Heat Shock Protein”, J. Biol. Chem., 262(32):15329-15369 (1987).
Barrios et al., “Heat shock proteins as carrier molecules: in vivo helper effect mediated byEscherichia coliGroEL and DnaK proteins requires cross-linking with antigen,” Clin. Exp. Immunol., 98:229-233 (1994).
Barrios et al., “Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming,” Eur. J. Immunol., 22:1365-1372 (1992).
Beech et al., “CD4+ Th2 cells specific for mycobacterial 65-kilodalton heat shock protein protect against pristane-induced arthritis,” J. Immunol. 159:3692-3697 (1997).
Bennett et al., “Help for Cytotoxic-T-cell Responses is Mediated by CD40 Signalling,” Nature 393:478-480 (Jun. 4, 1998).
Bertelli et al., “BCG-Induced Resistance inTrypanosoma cruziExperimental Infections,” Tropenmed Parasitol, 32:93-96 (1981).
Birk et al., “T-cell autoimmunity in type 1 diabetes mellitus,” Curr. Opin. Immunol., 5:903-909 (1993).
Blachere et al., “Heat Shock Protein-Peptide Complexes, Reconstituted in Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity,” J. Exp. Med. 186(8):1315-1322 (Oct. 20, 1997).
Blander and Horwitz, “Major Cytoplasmic Membrane Protein of Legionella Pneumophila, a Genus Common Antigen and Member of the hsp 60 Family of Heat Shock Proteins, Induces Protective Immunity in a Guinea Pig Model of Legionnaires' Disease,” J. Clin. Invest., 91:717-723 (1993).
Breloer et al., “In Vivo and In Vitro Activation of T Cells After Administration of Ag-Negative Heat Shock Proteins,” J. of Immun. 162:3141-3147 (1999).
Cassell et al., “A Phase II Study on the Postsurgical Management of Stage Malignant Melanoma With a Newcastle Disease Virus Oncolysate,” Cancer, 52:856-860 (Sep. 1983).
Cassell et al., “Viral Oncolysate in the Management of Malignant Melanoma, I. Preparation of the Oncolysate and Measurement of Immunologic Responses” Cancer, 40:672-679 (Aug. 1977).
Catelli et al., “The common 90-kd protein component of non-transformed ‘8S’ steroid receptors is a heat-shock protein”, EMBO J., 4(12):3131-3135 (1985).
Chandrasekhar et al., “Purification and Properties of the groES Morphogenetic Protein ofEscherichia coli”, J. Biol. Chem., 261(26):12414-12419 (1986).
Chen et al., “Human 60-kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System,” J. of Immunol. 162:3212-3219 (1999).
Chu et al., “Cancer Immunotherapy Using Adjuvant-free, Fusion Protein Encoding M. bovis BCG HSP65 and HPV16 E7”, Faseb Journal, 12(5):A909 (Mar. 20, 1998).
Chu et al., “Immunotherapy of a Human Papillomavirus (HPV) Type 16 E7-Expressing Tumour By Administration of Fusion Protein ComprisingMycobacteria bovisBacille Calmette-Guérin (BCG) hsp65 and HPV16 E7”, Clin. Exp. Immunol., 121:216-226 (2000).
Cohen et al., “Immunity to 60 kDa heat shock protein in autoimmune diabetes,” Diab. Nutr. Metab., 9(4):229-232 (1996).
Cohen, “Jitters jeopardize AIDS vaccine trials ,” Science, 262: 980-981 (1993).
Dahlseid et al., “PBP74, a new member of the mammalian 70-kDa heat shock protein family, is a mitochondrial protein,” Mol Biol Cell. 5(11):1265-1275 (1994).
De Velasco et al., “Synthetic Peptides Representing T-Cell Epitopes Act as Carri
Liu Hongwei
Mizzen Lee A.
Siegel Marvin
Fish & Richardson P.C.
Mosher Mary E.
Stressgen Biotechnologies Corporation
LandOfFree
Hepatitis B virus treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis B virus treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis B virus treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387894